Anbio Biotechnology (NNNN) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Achieve Life Sciences is the larger company by market cap ($573.2 million vs $145.7 million), about 3.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | QUIT |
|---|---|---|
| Share price | $3.32 | $5.56 |
| Market cap | $145.72M | $573.25M |
| 1-day change | -9.04% | -5.28% |
| YTD return | -88.96% | — |
| 1-year return | -86.02% | — |
| P/E ratio (TTM) | 22.13 | — |
| EPS (TTM) | $0.15 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.65M | — |
| Revenue growth (YoY) | +5.64% | — |
| Net income (latest FY) | $6.40M | $-54.65M |
| Gross margin | 87.24% | — |
| Operating margin | 66.70% | — |
| Net margin | 74.06% | — |
| 52-week high | $44.73 | $8.64 |
| 52-week low | $3.09 | $2.62 |
| Distance from 52-week high | -92.58% | -35.65% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +162.23% |
| Average volume | 128.35K | 1.38M |
| Shares outstanding | 43.89M | 103.10M |
| Employees | 27 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 3.9 times larger than Anbio Biotechnology by market value ($573.25M vs $145.72M).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
NNNN vs QUIT FAQ
Which is bigger, Anbio Biotechnology or Achieve Life Sciences?
Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $145.72M for Anbio Biotechnology (NNNN).
Are Anbio Biotechnology and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.